Next Science Ltd traded at 0.15 this Wednesday December 31st, increasing 0.01 or 3.57 percent since the previous trading session. Looking back, over the last four weeks, Next Science gained 0 percent. Over the last 12 months, its price rose by 26.09 percent. Looking ahead, we forecast Next Science Ltd to be priced at 0.14 by the end of this quarter and at 0.13 in one year, according to Trading Economics global macro models projections and analysts expectations.
Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.